nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—CCL2—neck—thyroid cancer	0.0165	0.147	CbGeAlD
Danazol—Hoarseness—Sorafenib—thyroid cancer	0.0132	0.0301	CcSEcCtD
Danazol—Interstitial lung disease—Vandetanib—thyroid cancer	0.0121	0.0278	CcSEcCtD
Danazol—Interstitial pneumonia—Sorafenib—thyroid cancer	0.012	0.0274	CcSEcCtD
Danazol—Acne—Vandetanib—thyroid cancer	0.0102	0.0234	CcSEcCtD
Danazol—CCL2—trachea—thyroid cancer	0.00992	0.0886	CbGeAlD
Danazol—SHBG—neck—thyroid cancer	0.00962	0.0859	CbGeAlD
Danazol—Cataract—Vandetanib—thyroid cancer	0.00903	0.0206	CcSEcCtD
Danazol—GNRHR—head—thyroid cancer	0.00892	0.0796	CbGeAlD
Danazol—Interstitial lung disease—Sorafenib—thyroid cancer	0.00819	0.0187	CcSEcCtD
Danazol—Oropharyngeal discomfort—Sorafenib—thyroid cancer	0.00797	0.0182	CcSEcCtD
Danazol—CCL2—thyroid gland—thyroid cancer	0.00785	0.0701	CbGeAlD
Danazol—Dysphonia—Sorafenib—thyroid cancer	0.00705	0.0161	CcSEcCtD
Danazol—Gastroenteritis—Vandetanib—thyroid cancer	0.00704	0.0161	CcSEcCtD
Danazol—CCL2—head—thyroid cancer	0.00696	0.0622	CbGeAlD
Danazol—ESR1—neck—thyroid cancer	0.00678	0.0605	CbGeAlD
Danazol—Pigmentation disorder—Epirubicin—thyroid cancer	0.00642	0.0147	CcSEcCtD
Danazol—Pigmentation disorder—Doxorubicin—thyroid cancer	0.00594	0.0136	CcSEcCtD
Danazol—Pancreatitis—Vandetanib—thyroid cancer	0.00529	0.0121	CcSEcCtD
Danazol—Laboratory test abnormal—Epirubicin—thyroid cancer	0.00513	0.0117	CcSEcCtD
Danazol—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00492	0.0113	CcSEcCtD
Danazol—CCL2—lymph node—thyroid cancer	0.00487	0.0435	CbGeAlD
Danazol—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00482	0.011	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00477	0.0109	CcSEcCtD
Danazol—Laboratory test abnormal—Doxorubicin—thyroid cancer	0.00475	0.0109	CcSEcCtD
Danazol—Haematuria—Vandetanib—thyroid cancer	0.00459	0.0105	CcSEcCtD
Danazol—SHBG—thyroid gland—thyroid cancer	0.00458	0.0409	CbGeAlD
Danazol—Haemoglobin—Vandetanib—thyroid cancer	0.00434	0.00992	CcSEcCtD
Danazol—Haemorrhage—Vandetanib—thyroid cancer	0.00432	0.00987	CcSEcCtD
Danazol—Visual impairment—Vandetanib—thyroid cancer	0.00416	0.00951	CcSEcCtD
Danazol—PGR—thyroid gland—thyroid cancer	0.00412	0.0368	CbGeAlD
Danazol—Erythema multiforme—Vandetanib—thyroid cancer	0.00408	0.00933	CcSEcCtD
Danazol—Mood swings—Sorafenib—thyroid cancer	0.00399	0.00911	CcSEcCtD
Danazol—Abdominal pain upper—Sorafenib—thyroid cancer	0.00385	0.00879	CcSEcCtD
Danazol—Alopecia—Vandetanib—thyroid cancer	0.00382	0.00872	CcSEcCtD
Danazol—Gingival bleeding—Epirubicin—thyroid cancer	0.00378	0.00863	CcSEcCtD
Danazol—CYP19A1—thyroid gland—thyroid cancer	0.00371	0.0331	CbGeAlD
Danazol—PGR—head—thyroid cancer	0.00366	0.0327	CbGeAlD
Danazol—Muscle spasms—Vandetanib—thyroid cancer	0.00361	0.00826	CcSEcCtD
Danazol—Pancreatitis—Sorafenib—thyroid cancer	0.00357	0.00815	CcSEcCtD
Danazol—Vision blurred—Vandetanib—thyroid cancer	0.00354	0.0081	CcSEcCtD
Danazol—Pelvic pain—Epirubicin—thyroid cancer	0.00352	0.00805	CcSEcCtD
Danazol—Tremor—Vandetanib—thyroid cancer	0.00352	0.00805	CcSEcCtD
Danazol—Gingival bleeding—Doxorubicin—thyroid cancer	0.00349	0.00799	CcSEcCtD
Danazol—Loss of consciousness—Vandetanib—thyroid cancer	0.0033	0.00755	CcSEcCtD
Danazol—CYP19A1—head—thyroid cancer	0.00329	0.0294	CbGeAlD
Danazol—AR—thyroid gland—thyroid cancer	0.00329	0.0293	CbGeAlD
Danazol—Pelvic pain—Doxorubicin—thyroid cancer	0.00326	0.00745	CcSEcCtD
Danazol—Convulsion—Vandetanib—thyroid cancer	0.00326	0.00744	CcSEcCtD
Danazol—Hypertension—Vandetanib—thyroid cancer	0.00324	0.00742	CcSEcCtD
Danazol—ESR1—thyroid gland—thyroid cancer	0.00322	0.0288	CbGeAlD
Danazol—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00322	0.00735	CcSEcCtD
Danazol—Arthralgia—Vandetanib—thyroid cancer	0.0032	0.00731	CcSEcCtD
Danazol—Acute coronary syndrome—Sorafenib—thyroid cancer	0.0032	0.00731	CcSEcCtD
Danazol—Anxiety—Vandetanib—thyroid cancer	0.00319	0.00729	CcSEcCtD
Danazol—Myocardial infarction—Sorafenib—thyroid cancer	0.00318	0.00727	CcSEcCtD
Danazol—Jaundice—Sorafenib—thyroid cancer	0.00316	0.00723	CcSEcCtD
Danazol—Seborrhoeic dermatitis—Epirubicin—thyroid cancer	0.00314	0.00719	CcSEcCtD
Danazol—Oedema—Vandetanib—thyroid cancer	0.00307	0.00701	CcSEcCtD
Danazol—Thrombosis—Epirubicin—thyroid cancer	0.00303	0.00692	CcSEcCtD
Danazol—Thrombocytopenia—Vandetanib—thyroid cancer	0.003	0.00686	CcSEcCtD
Danazol—Haemoglobin—Sorafenib—thyroid cancer	0.00293	0.00669	CcSEcCtD
Danazol—AR—head—thyroid cancer	0.00291	0.026	CbGeAlD
Danazol—Haemorrhage—Sorafenib—thyroid cancer	0.00291	0.00666	CcSEcCtD
Danazol—Seborrhoeic dermatitis—Doxorubicin—thyroid cancer	0.00291	0.00665	CcSEcCtD
Danazol—ESR1—head—thyroid cancer	0.00286	0.0256	CbGeAlD
Danazol—Thrombosis—Doxorubicin—thyroid cancer	0.0028	0.0064	CcSEcCtD
Danazol—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00279	0.00639	CcSEcCtD
Danazol—Paraesthesia—Vandetanib—thyroid cancer	0.00275	0.00629	CcSEcCtD
Danazol—Erythema multiforme—Sorafenib—thyroid cancer	0.00275	0.00629	CcSEcCtD
Danazol—Flushing—Sorafenib—thyroid cancer	0.0027	0.00618	CcSEcCtD
Danazol—Dyspepsia—Vandetanib—thyroid cancer	0.0027	0.00617	CcSEcCtD
Danazol—Fatigue—Vandetanib—thyroid cancer	0.00264	0.00604	CcSEcCtD
Danazol—Constipation—Vandetanib—thyroid cancer	0.00262	0.00599	CcSEcCtD
Danazol—Dysphonia—Epirubicin—thyroid cancer	0.00261	0.00595	CcSEcCtD
Danazol—Alopecia—Sorafenib—thyroid cancer	0.00257	0.00588	CcSEcCtD
Danazol—PGR—lymph node—thyroid cancer	0.00256	0.0229	CbGeAlD
Danazol—Amenorrhoea—Epirubicin—thyroid cancer	0.00244	0.00558	CcSEcCtD
Danazol—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00244	0.00558	CcSEcCtD
Danazol—Muscle spasms—Sorafenib—thyroid cancer	0.00244	0.00557	CcSEcCtD
Danazol—Body temperature increased—Vandetanib—thyroid cancer	0.00242	0.00554	CcSEcCtD
Danazol—Dysphonia—Doxorubicin—thyroid cancer	0.00241	0.00551	CcSEcCtD
Danazol—CYP19A1—lymph node—thyroid cancer	0.00231	0.0206	CbGeAlD
Danazol—Syncope—Sorafenib—thyroid cancer	0.00227	0.0052	CcSEcCtD
Danazol—Leukopenia—Sorafenib—thyroid cancer	0.00227	0.00519	CcSEcCtD
Danazol—Amenorrhoea—Doxorubicin—thyroid cancer	0.00226	0.00516	CcSEcCtD
Danazol—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00226	0.00516	CcSEcCtD
Danazol—Loss of consciousness—Sorafenib—thyroid cancer	0.00223	0.00509	CcSEcCtD
Danazol—Asthenia—Vandetanib—thyroid cancer	0.0022	0.00503	CcSEcCtD
Danazol—Hypertension—Sorafenib—thyroid cancer	0.00219	0.005	CcSEcCtD
Danazol—Pruritus—Vandetanib—thyroid cancer	0.00217	0.00496	CcSEcCtD
Danazol—Arthralgia—Sorafenib—thyroid cancer	0.00216	0.00493	CcSEcCtD
Danazol—AR—lymph node—thyroid cancer	0.00204	0.0182	CbGeAlD
Danazol—Shock—Sorafenib—thyroid cancer	0.00204	0.00465	CcSEcCtD
Danazol—Fluid retention—Epirubicin—thyroid cancer	0.00203	0.00465	CcSEcCtD
Danazol—Dizziness—Vandetanib—thyroid cancer	0.00203	0.00464	CcSEcCtD
Danazol—Thrombocytopenia—Sorafenib—thyroid cancer	0.00203	0.00463	CcSEcCtD
Danazol—ESR1—lymph node—thyroid cancer	0.002	0.0179	CbGeAlD
Danazol—Vomiting—Vandetanib—thyroid cancer	0.00195	0.00446	CcSEcCtD
Danazol—Rash—Vandetanib—thyroid cancer	0.00193	0.00442	CcSEcCtD
Danazol—Dermatitis—Vandetanib—thyroid cancer	0.00193	0.00442	CcSEcCtD
Danazol—Headache—Vandetanib—thyroid cancer	0.00192	0.00439	CcSEcCtD
Danazol—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00189	0.00431	CcSEcCtD
Danazol—Fluid retention—Doxorubicin—thyroid cancer	0.00188	0.0043	CcSEcCtD
Danazol—Nausea—Vandetanib—thyroid cancer	0.00182	0.00416	CcSEcCtD
Danazol—Dyspepsia—Sorafenib—thyroid cancer	0.00182	0.00416	CcSEcCtD
Danazol—Fatigue—Sorafenib—thyroid cancer	0.00178	0.00408	CcSEcCtD
Danazol—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00178	0.00407	CcSEcCtD
Danazol—Photosensitivity—Epirubicin—thyroid cancer	0.00177	0.00405	CcSEcCtD
Danazol—Constipation—Sorafenib—thyroid cancer	0.00177	0.00404	CcSEcCtD
Danazol—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00165	0.00376	CcSEcCtD
Danazol—Urticaria—Sorafenib—thyroid cancer	0.00164	0.00376	CcSEcCtD
Danazol—Photosensitivity—Doxorubicin—thyroid cancer	0.00164	0.00375	CcSEcCtD
Danazol—Body temperature increased—Sorafenib—thyroid cancer	0.00164	0.00374	CcSEcCtD
Danazol—Migraine—Epirubicin—thyroid cancer	0.00153	0.0035	CcSEcCtD
Danazol—Affect lability—Epirubicin—thyroid cancer	0.00153	0.0035	CcSEcCtD
Danazol—Asthenia—Sorafenib—thyroid cancer	0.00148	0.00339	CcSEcCtD
Danazol—Mood swings—Epirubicin—thyroid cancer	0.00147	0.00337	CcSEcCtD
Danazol—Pruritus—Sorafenib—thyroid cancer	0.00146	0.00335	CcSEcCtD
Danazol—Abdominal pain upper—Epirubicin—thyroid cancer	0.00142	0.00325	CcSEcCtD
Danazol—Affect lability—Doxorubicin—thyroid cancer	0.00142	0.00324	CcSEcCtD
Danazol—Migraine—Doxorubicin—thyroid cancer	0.00142	0.00324	CcSEcCtD
Danazol—Dizziness—Sorafenib—thyroid cancer	0.00137	0.00313	CcSEcCtD
Danazol—Mood swings—Doxorubicin—thyroid cancer	0.00136	0.00312	CcSEcCtD
Danazol—Eosinophilia—Epirubicin—thyroid cancer	0.00133	0.00304	CcSEcCtD
Danazol—Pancreatitis—Epirubicin—thyroid cancer	0.00132	0.00301	CcSEcCtD
Danazol—Vomiting—Sorafenib—thyroid cancer	0.00132	0.00301	CcSEcCtD
Danazol—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00131	0.00301	CcSEcCtD
Danazol—Rash—Sorafenib—thyroid cancer	0.0013	0.00298	CcSEcCtD
Danazol—Dermatitis—Sorafenib—thyroid cancer	0.0013	0.00298	CcSEcCtD
Danazol—Headache—Sorafenib—thyroid cancer	0.0013	0.00296	CcSEcCtD
Danazol—Eosinophilia—Doxorubicin—thyroid cancer	0.00123	0.00282	CcSEcCtD
Danazol—Nausea—Sorafenib—thyroid cancer	0.00123	0.00281	CcSEcCtD
Danazol—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00123	0.00281	CcSEcCtD
Danazol—Weight increased—Epirubicin—thyroid cancer	0.00122	0.0028	CcSEcCtD
Danazol—Pancreatitis—Doxorubicin—thyroid cancer	0.00122	0.00279	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00119	0.00272	CcSEcCtD
Danazol—Jaundice—Epirubicin—thyroid cancer	0.00117	0.00267	CcSEcCtD
Danazol—Sweating—Epirubicin—thyroid cancer	0.00115	0.00263	CcSEcCtD
Danazol—Haematuria—Epirubicin—thyroid cancer	0.00114	0.00261	CcSEcCtD
Danazol—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00114	0.0026	CcSEcCtD
Danazol—Weight increased—Doxorubicin—thyroid cancer	0.00113	0.00259	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.0011	0.00251	CcSEcCtD
Danazol—Haemoglobin—Epirubicin—thyroid cancer	0.00108	0.00247	CcSEcCtD
Danazol—Jaundice—Doxorubicin—thyroid cancer	0.00108	0.00247	CcSEcCtD
Danazol—Haemorrhage—Epirubicin—thyroid cancer	0.00108	0.00246	CcSEcCtD
Danazol—Sweating—Doxorubicin—thyroid cancer	0.00106	0.00243	CcSEcCtD
Danazol—Haematuria—Doxorubicin—thyroid cancer	0.00106	0.00242	CcSEcCtD
Danazol—Visual impairment—Epirubicin—thyroid cancer	0.00104	0.00237	CcSEcCtD
Danazol—Erythema multiforme—Epirubicin—thyroid cancer	0.00102	0.00233	CcSEcCtD
Danazol—Haemoglobin—Doxorubicin—thyroid cancer	0.001	0.00229	CcSEcCtD
Danazol—Flushing—Epirubicin—thyroid cancer	0.000999	0.00228	CcSEcCtD
Danazol—Haemorrhage—Doxorubicin—thyroid cancer	0.000996	0.00228	CcSEcCtD
Danazol—Chills—Epirubicin—thyroid cancer	0.000966	0.00221	CcSEcCtD
Danazol—Visual impairment—Doxorubicin—thyroid cancer	0.00096	0.00219	CcSEcCtD
Danazol—Alopecia—Epirubicin—thyroid cancer	0.000951	0.00217	CcSEcCtD
Danazol—Erythema multiforme—Doxorubicin—thyroid cancer	0.000942	0.00215	CcSEcCtD
Danazol—Flushing—Doxorubicin—thyroid cancer	0.000924	0.00211	CcSEcCtD
Danazol—Tension—Epirubicin—thyroid cancer	0.000919	0.0021	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—TRIM33—thyroid cancer	0.000918	0.00204	CbGpPWpGaD
Danazol—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000914	0.00203	CbGpPWpGaD
Danazol—ESR1—Estrogen signaling pathway—AKT1—thyroid cancer	0.000911	0.00202	CbGpPWpGaD
Danazol—Nervousness—Epirubicin—thyroid cancer	0.00091	0.00208	CcSEcCtD
Danazol—Back pain—Epirubicin—thyroid cancer	0.000906	0.00207	CcSEcCtD
Danazol—Muscle spasms—Epirubicin—thyroid cancer	0.000901	0.00206	CcSEcCtD
Danazol—CYP19A1—FSH signaling pathway—AKT1—thyroid cancer	0.000895	0.00199	CbGpPWpGaD
Danazol—Chills—Doxorubicin—thyroid cancer	0.000894	0.00204	CcSEcCtD
Danazol—PGR—Gene Expression—TRIM33—thyroid cancer	0.00089	0.00198	CbGpPWpGaD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—NRAS—thyroid cancer	0.000888	0.00197	CbGpPWpGaD
Danazol—CCL2—TNF alpha Signaling Pathway—AKT1—thyroid cancer	0.000888	0.00197	CbGpPWpGaD
Danazol—Vision blurred—Epirubicin—thyroid cancer	0.000883	0.00202	CcSEcCtD
Danazol—Alopecia—Doxorubicin—thyroid cancer	0.00088	0.00201	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000871	0.00193	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—CDK1—thyroid cancer	0.000868	0.00193	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000867	0.00192	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—TP53—thyroid cancer	0.000862	0.00191	CbGpPWpGaD
Danazol—Tension—Doxorubicin—thyroid cancer	0.000851	0.00194	CcSEcCtD
Danazol—PGR—Generic Transcription Pathway—MEN1—thyroid cancer	0.000849	0.00189	CbGpPWpGaD
Danazol—Nervousness—Doxorubicin—thyroid cancer	0.000842	0.00192	CcSEcCtD
Danazol—Vertigo—Epirubicin—thyroid cancer	0.000842	0.00192	CcSEcCtD
Danazol—Syncope—Epirubicin—thyroid cancer	0.00084	0.00192	CcSEcCtD
Danazol—Leukopenia—Epirubicin—thyroid cancer	0.000839	0.00192	CcSEcCtD
Danazol—Back pain—Doxorubicin—thyroid cancer	0.000839	0.00192	CcSEcCtD
Danazol—GNRHR—GPCR downstream signaling—TSHR—thyroid cancer	0.000836	0.00186	CbGpPWpGaD
Danazol—Muscle spasms—Doxorubicin—thyroid cancer	0.000834	0.0019	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—TSHR—thyroid cancer	0.00083	0.00184	CbGpPWpGaD
Danazol—Palpitations—Epirubicin—thyroid cancer	0.000828	0.00189	CcSEcCtD
Danazol—Loss of consciousness—Epirubicin—thyroid cancer	0.000824	0.00188	CcSEcCtD
Danazol—Vision blurred—Doxorubicin—thyroid cancer	0.000817	0.00187	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000816	0.00181	CbGpPWpGaD
Danazol—CYP19A1—Biological oxidations—RXRA—thyroid cancer	0.000815	0.00181	CbGpPWpGaD
Danazol—Convulsion—Epirubicin—thyroid cancer	0.000812	0.00186	CcSEcCtD
Danazol—ESR1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.00081	0.0018	CbGpPWpGaD
Danazol—Hypertension—Epirubicin—thyroid cancer	0.000809	0.00185	CcSEcCtD
Danazol—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000806	0.00179	CbGpPWpGaD
Danazol—Arthralgia—Epirubicin—thyroid cancer	0.000798	0.00182	CcSEcCtD
Danazol—Anxiety—Epirubicin—thyroid cancer	0.000795	0.00182	CcSEcCtD
Danazol—ESR1—Generic Transcription Pathway—THRB—thyroid cancer	0.000785	0.00174	CbGpPWpGaD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—thyroid cancer	0.000784	0.00174	CbGpPWpGaD
Danazol—Vertigo—Doxorubicin—thyroid cancer	0.000779	0.00178	CcSEcCtD
Danazol—Syncope—Doxorubicin—thyroid cancer	0.000777	0.00178	CcSEcCtD
Danazol—Leukopenia—Doxorubicin—thyroid cancer	0.000776	0.00177	CcSEcCtD
Danazol—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000771	0.00171	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—CCND1—thyroid cancer	0.000771	0.00171	CbGpPWpGaD
Danazol—Palpitations—Doxorubicin—thyroid cancer	0.000766	0.00175	CcSEcCtD
Danazol—Oedema—Epirubicin—thyroid cancer	0.000765	0.00175	CcSEcCtD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—KRAS—thyroid cancer	0.000765	0.0017	CbGpPWpGaD
Danazol—Loss of consciousness—Doxorubicin—thyroid cancer	0.000762	0.00174	CcSEcCtD
Danazol—AR—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000761	0.00169	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—TSHR—thyroid cancer	0.000759	0.00168	CbGpPWpGaD
Danazol—Shock—Epirubicin—thyroid cancer	0.000752	0.00172	CcSEcCtD
Danazol—Convulsion—Doxorubicin—thyroid cancer	0.000751	0.00172	CcSEcCtD
Danazol—Thrombocytopenia—Epirubicin—thyroid cancer	0.000749	0.00171	CcSEcCtD
Danazol—Hypertension—Doxorubicin—thyroid cancer	0.000748	0.00171	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000747	0.00166	CbGpPWpGaD
Danazol—Tachycardia—Epirubicin—thyroid cancer	0.000746	0.00171	CcSEcCtD
Danazol—Hyperhidrosis—Epirubicin—thyroid cancer	0.000739	0.00169	CcSEcCtD
Danazol—Arthralgia—Doxorubicin—thyroid cancer	0.000738	0.00169	CcSEcCtD
Danazol—Anxiety—Doxorubicin—thyroid cancer	0.000736	0.00168	CcSEcCtD
Danazol—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—thyroid cancer	0.000722	0.0016	CbGpPWpGaD
Danazol—AR—Androgen receptor signaling pathway—CCND1—thyroid cancer	0.00072	0.0016	CbGpPWpGaD
Danazol—Oedema—Doxorubicin—thyroid cancer	0.000708	0.00162	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—PTCH1—thyroid cancer	0.000706	0.00157	CbGpPWpGaD
Danazol—ESR1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000697	0.00155	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—NRG1—thyroid cancer	0.000697	0.00155	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000697	0.00159	CcSEcCtD
Danazol—Shock—Doxorubicin—thyroid cancer	0.000696	0.00159	CcSEcCtD
Danazol—AR—Androgen receptor signaling pathway—PTEN—thyroid cancer	0.000695	0.00154	CbGpPWpGaD
Danazol—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000693	0.00158	CcSEcCtD
Danazol—Tachycardia—Doxorubicin—thyroid cancer	0.000691	0.00158	CcSEcCtD
Danazol—ESR1—Regulation of Telomerase—CCND1—thyroid cancer	0.000688	0.00153	CbGpPWpGaD
Danazol—Paraesthesia—Epirubicin—thyroid cancer	0.000687	0.00157	CcSEcCtD
Danazol—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000684	0.00156	CcSEcCtD
Danazol—AR—Gene Expression—TRIM33—thyroid cancer	0.000678	0.00151	CbGpPWpGaD
Danazol—Dyspepsia—Epirubicin—thyroid cancer	0.000673	0.00154	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—CCND1—thyroid cancer	0.000672	0.00149	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000671	0.00149	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TCF7L1—thyroid cancer	0.00067	0.00149	CbGpPWpGaD
Danazol—Fatigue—Epirubicin—thyroid cancer	0.000659	0.00151	CcSEcCtD
Danazol—ESR1—LKB1 signaling events—TP53—thyroid cancer	0.000654	0.00145	CbGpPWpGaD
Danazol—Constipation—Epirubicin—thyroid cancer	0.000654	0.00149	CcSEcCtD
Danazol—GNRHR—GPCR downstream signaling—SST—thyroid cancer	0.00065	0.00144	CbGpPWpGaD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—HRAS—thyroid cancer	0.00065	0.00144	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—PTEN—thyroid cancer	0.000649	0.00144	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—MEN1—thyroid cancer	0.000647	0.00144	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000647	0.00144	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—SST—thyroid cancer	0.000645	0.00143	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—PTCH1—thyroid cancer	0.000645	0.00143	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000645	0.00147	CcSEcCtD
Danazol—PGR—Gene Expression—THRB—thyroid cancer	0.000644	0.00143	CbGpPWpGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000638	0.00142	CbGpPWpGaD
Danazol—ESR1—Leptin signaling pathway—CCND1—thyroid cancer	0.000636	0.00141	CbGpPWpGaD
Danazol—Paraesthesia—Doxorubicin—thyroid cancer	0.000635	0.00145	CcSEcCtD
Danazol—GNRHR—GPCR downstream signaling—CALCA—thyroid cancer	0.000626	0.00139	CbGpPWpGaD
Danazol—Dyspepsia—Doxorubicin—thyroid cancer	0.000623	0.00142	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—CALCA—thyroid cancer	0.000621	0.00138	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TCF7L1—thyroid cancer	0.000613	0.00136	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CALCB—thyroid cancer	0.000611	0.00136	CbGpPWpGaD
Danazol—Fatigue—Doxorubicin—thyroid cancer	0.00061	0.00139	CcSEcCtD
Danazol—Urticaria—Epirubicin—thyroid cancer	0.000607	0.00139	CcSEcCtD
Danazol—Constipation—Doxorubicin—thyroid cancer	0.000605	0.00138	CcSEcCtD
Danazol—Body temperature increased—Epirubicin—thyroid cancer	0.000605	0.00138	CcSEcCtD
Danazol—CYP19A1—Metabolism—MINPP1—thyroid cancer	0.000599	0.00133	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—PTEN—thyroid cancer	0.000595	0.00132	CbGpPWpGaD
Danazol—ESR1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000593	0.00132	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—SST—thyroid cancer	0.00059	0.00131	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TRIM33—thyroid cancer	0.000579	0.00129	CbGpPWpGaD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—AKT1—thyroid cancer	0.000574	0.00127	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CALCA—thyroid cancer	0.000568	0.00126	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—RXRA—thyroid cancer	0.000568	0.00126	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CDK1—thyroid cancer	0.000562	0.00125	CbGpPWpGaD
Danazol—Urticaria—Doxorubicin—thyroid cancer	0.000562	0.00128	CcSEcCtD
Danazol—Body temperature increased—Doxorubicin—thyroid cancer	0.000559	0.00128	CcSEcCtD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000556	0.00124	CbGpPWpGaD
Danazol—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000553	0.00123	CbGpPWpGaD
Danazol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00055	0.00122	CbGpPWpGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000549	0.00122	CbGpPWpGaD
Danazol—Asthenia—Epirubicin—thyroid cancer	0.000549	0.00125	CcSEcCtD
Danazol—AR—Coregulation of Androgen receptor activity—AKT1—thyroid cancer	0.000542	0.0012	CbGpPWpGaD
Danazol—Pruritus—Epirubicin—thyroid cancer	0.000541	0.00124	CcSEcCtD
Danazol—PGR—Signaling by ERBB4—NRAS—thyroid cancer	0.000531	0.00118	CbGpPWpGaD
Danazol—ESR1—Gene Expression—TRIM33—thyroid cancer	0.000523	0.00116	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CDK1—thyroid cancer	0.000514	0.00114	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—NDUFA13—thyroid cancer	0.000509	0.00113	CbGpPWpGaD
Danazol—Asthenia—Doxorubicin—thyroid cancer	0.000508	0.00116	CcSEcCtD
Danazol—Dizziness—Epirubicin—thyroid cancer	0.000506	0.00116	CcSEcCtD
Danazol—Pruritus—Doxorubicin—thyroid cancer	0.000501	0.00114	CcSEcCtD
Danazol—ESR1—Generic Transcription Pathway—MEN1—thyroid cancer	0.000498	0.00111	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000498	0.00111	CbGpPWpGaD
Danazol—AR—Gene Expression—THRB—thyroid cancer	0.000491	0.00109	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TSHR—thyroid cancer	0.00049	0.00109	CbGpPWpGaD
Danazol—Vomiting—Epirubicin—thyroid cancer	0.000486	0.00111	CcSEcCtD
Danazol—CCL2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000482	0.00107	CbGpPWpGaD
Danazol—Rash—Epirubicin—thyroid cancer	0.000482	0.0011	CcSEcCtD
Danazol—Dermatitis—Epirubicin—thyroid cancer	0.000482	0.0011	CcSEcCtD
Danazol—Headache—Epirubicin—thyroid cancer	0.000479	0.00109	CcSEcCtD
Danazol—CYP19A1—Metabolism—CHST14—thyroid cancer	0.000479	0.00106	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000472	0.00105	CbGpPWpGaD
Danazol—Dizziness—Doxorubicin—thyroid cancer	0.000468	0.00107	CcSEcCtD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000466	0.00104	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MEN1—thyroid cancer	0.000461	0.00102	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—KRAS—thyroid cancer	0.000457	0.00101	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000455	0.00101	CbGpPWpGaD
Danazol—Nausea—Epirubicin—thyroid cancer	0.000454	0.00104	CcSEcCtD
Danazol—Vomiting—Doxorubicin—thyroid cancer	0.00045	0.00103	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—TSHR—thyroid cancer	0.000448	0.000995	CbGpPWpGaD
Danazol—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000448	0.000994	CbGpPWpGaD
Danazol—Rash—Doxorubicin—thyroid cancer	0.000446	0.00102	CcSEcCtD
Danazol—Dermatitis—Doxorubicin—thyroid cancer	0.000446	0.00102	CcSEcCtD
Danazol—Headache—Doxorubicin—thyroid cancer	0.000443	0.00101	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—TP53—thyroid cancer	0.000443	0.000983	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000441	0.000979	CbGpPWpGaD
Danazol—PGR—Gene Expression—TPR—thyroid cancer	0.000435	0.000965	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—RXRA—thyroid cancer	0.000433	0.000961	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000433	0.000961	CbGpPWpGaD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000432	0.000959	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MEN1—thyroid cancer	0.000422	0.000936	CbGpPWpGaD
Danazol—Nausea—Doxorubicin—thyroid cancer	0.00042	0.000961	CcSEcCtD
Danazol—CCL2—Signaling Pathways—PTCH1—thyroid cancer	0.000417	0.000925	CbGpPWpGaD
Danazol—PGR—Gene Expression—MEN1—thyroid cancer	0.000409	0.000908	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000406	0.000901	CbGpPWpGaD
Danazol—ESR1—Leptin signaling pathway—HRAS—thyroid cancer	0.000401	0.00089	CbGpPWpGaD
Danazol—AR—Androgen receptor signaling pathway—AKT1—thyroid cancer	0.000401	0.000889	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000392	0.00087	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000391	0.000868	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—HRAS—thyroid cancer	0.000388	0.000862	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TCF7L1—thyroid cancer	0.000386	0.000857	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—HPGD—thyroid cancer	0.000386	0.000857	CbGpPWpGaD
Danazol—ESR1—Regulation of Telomerase—AKT1—thyroid cancer	0.000383	0.00085	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SST—thyroid cancer	0.000381	0.000846	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PTCH1—thyroid cancer	0.000381	0.000846	CbGpPWpGaD
Danazol—ESR1—Gene Expression—THRB—thyroid cancer	0.000378	0.000839	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000377	0.000838	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CALCA—thyroid cancer	0.000367	0.000815	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000364	0.000807	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—PPARG—thyroid cancer	0.000359	0.000796	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CALCB—thyroid cancer	0.000358	0.000796	CbGpPWpGaD
Danazol—ESR1—Leptin signaling pathway—AKT1—thyroid cancer	0.000354	0.000786	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000351	0.000779	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.00035	0.000776	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—PTEN—thyroid cancer	0.000349	0.000775	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SST—thyroid cancer	0.000349	0.000774	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—AKT1—thyroid cancer	0.000343	0.000761	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TRIM33—thyroid cancer	0.00034	0.000754	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CALCA—thyroid cancer	0.000336	0.000745	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—RXRA—thyroid cancer	0.000333	0.00074	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000333	0.00074	CbGpPWpGaD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000333	0.000739	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CDK1—thyroid cancer	0.000332	0.000737	CbGpPWpGaD
Danazol—AR—Gene Expression—TPR—thyroid cancer	0.000331	0.000735	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000313	0.000695	CbGpPWpGaD
Danazol—AR—Gene Expression—MEN1—thyroid cancer	0.000312	0.000691	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—NRAS—thyroid cancer	0.000311	0.000691	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000311	0.00069	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CDK1—thyroid cancer	0.000304	0.000674	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000301	0.000669	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000301	0.000668	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000291	0.000645	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.00029	0.000643	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TSHR—thyroid cancer	0.000283	0.000628	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000278	0.000617	CbGpPWpGaD
Danazol—PGR—Gene Expression—RXRA—thyroid cancer	0.000274	0.000607	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—PPARG—thyroid cancer	0.000273	0.000607	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000269	0.000598	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—KRAS—thyroid cancer	0.000268	0.000595	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000267	0.000594	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—NRG1—thyroid cancer	0.000267	0.000592	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MEN1—thyroid cancer	0.000266	0.00059	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000262	0.000583	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000258	0.000572	CbGpPWpGaD
Danazol—ESR1—Gene Expression—TPR—thyroid cancer	0.000255	0.000567	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—NRG1—thyroid cancer	0.000244	0.000541	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PTCH1—thyroid cancer	0.00024	0.000534	CbGpPWpGaD
Danazol—ESR1—Gene Expression—MEN1—thyroid cancer	0.00024	0.000533	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000239	0.000532	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TERT—thyroid cancer	0.000239	0.000531	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000238	0.000528	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—HIF1A—thyroid cancer	0.000229	0.000508	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—HRAS—thyroid cancer	0.000228	0.000506	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TCF7L1—thyroid cancer	0.000227	0.000503	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000226	0.000501	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000223	0.000496	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—TPR—thyroid cancer	0.000222	0.000492	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SST—thyroid cancer	0.00022	0.000488	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TERT—thyroid cancer	0.000219	0.000486	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PRKAR1A—thyroid cancer	0.000218	0.000484	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000218	0.000483	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CALCA—thyroid cancer	0.000212	0.00047	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—PPARG—thyroid cancer	0.000211	0.000467	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—HIF1A—thyroid cancer	0.000209	0.000465	CbGpPWpGaD
Danazol—AR—Gene Expression—RXRA—thyroid cancer	0.000208	0.000463	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000202	0.000449	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—NRAS—thyroid cancer	0.000202	0.000448	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—AKT1—thyroid cancer	0.000201	0.000446	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000198	0.00044	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000198	0.000439	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CDK1—thyroid cancer	0.000192	0.000425	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—BRAF—thyroid cancer	0.00019	0.000421	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—NRAS—thyroid cancer	0.000184	0.00041	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000175	0.000388	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—KRAS—thyroid cancer	0.000174	0.000385	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—BRAF—thyroid cancer	0.000173	0.000385	CbGpPWpGaD
Danazol—PGR—Gene Expression—PPARG—thyroid cancer	0.000173	0.000383	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000168	0.000372	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—SLC5A5—thyroid cancer	0.000166	0.000368	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TSHR—thyroid cancer	0.000166	0.000368	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000163	0.000362	CbGpPWpGaD
Danazol—ESR1—Gene Expression—RXRA—thyroid cancer	0.000161	0.000356	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—KRAS—thyroid cancer	0.000159	0.000352	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MEN1—thyroid cancer	0.000156	0.000346	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000156	0.000345	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—NRG1—thyroid cancer	0.000154	0.000341	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.000149	0.00033	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—HRAS—thyroid cancer	0.000148	0.000328	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PTCH1—thyroid cancer	0.000141	0.000313	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CHST14—thyroid cancer	0.00014	0.00031	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—RXRA—thyroid cancer	0.000139	0.000309	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CCND1—thyroid cancer	0.000138	0.000307	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TERT—thyroid cancer	0.000138	0.000307	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000136	0.000301	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—HRAS—thyroid cancer	0.000135	0.0003	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PTEN—thyroid cancer	0.000134	0.000296	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—HIF1A—thyroid cancer	0.000132	0.000293	CbGpPWpGaD
Danazol—AR—Gene Expression—PPARG—thyroid cancer	0.000132	0.000292	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—AKT1—thyroid cancer	0.000131	0.000291	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—AKT1—thyroid cancer	0.00013	0.000289	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SST—thyroid cancer	0.000129	0.000286	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCND1—thyroid cancer	0.000127	0.000281	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CALCA—thyroid cancer	0.000124	0.000276	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PTEN—thyroid cancer	0.000122	0.000271	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—AKT1—thyroid cancer	0.000119	0.000265	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—NRAS—thyroid cancer	0.000119	0.000264	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—HPGD—thyroid cancer	0.000113	0.00025	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CDK1—thyroid cancer	0.000112	0.00025	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—BRAF—thyroid cancer	0.000109	0.000243	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—NRAS—thyroid cancer	0.000109	0.000242	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—KRAS—thyroid cancer	0.000103	0.000228	CbGpPWpGaD
Danazol—ESR1—Gene Expression—PPARG—thyroid cancer	0.000101	0.000225	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—KRAS—thyroid cancer	9.38e-05	0.000208	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TP53—thyroid cancer	9.12e-05	0.000202	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—NRG1—thyroid cancer	9.03e-05	0.0002	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PPARG—thyroid cancer	8.8e-05	0.000195	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—HRAS—thyroid cancer	8.72e-05	0.000193	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TP53—thyroid cancer	8.34e-05	0.000185	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TERT—thyroid cancer	8.1e-05	0.00018	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCND1—thyroid cancer	7.98e-05	0.000177	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—HRAS—thyroid cancer	7.97e-05	0.000177	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—HIF1A—thyroid cancer	7.75e-05	0.000172	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PTEN—thyroid cancer	7.7e-05	0.000171	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—AKT1—thyroid cancer	7.7e-05	0.000171	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—AKT1—thyroid cancer	7.04e-05	0.000156	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PTGS2—thyroid cancer	6.93e-05	0.000154	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—NRAS—thyroid cancer	6.87e-05	0.000153	CbGpPWpGaD
Danazol—PGR—Gene Expression—AKT1—thyroid cancer	6.83e-05	0.000152	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—TPR—thyroid cancer	6.47e-05	0.000144	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—BRAF—thyroid cancer	6.42e-05	0.000142	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	6.36e-05	0.000141	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PTEN—thyroid cancer	6.04e-05	0.000134	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—KRAS—thyroid cancer	5.92e-05	0.000131	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TP53—thyroid cancer	5.26e-05	0.000117	CbGpPWpGaD
Danazol—AR—Gene Expression—AKT1—thyroid cancer	5.2e-05	0.000115	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—HRAS—thyroid cancer	5.03e-05	0.000112	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.84e-05	0.000107	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCND1—thyroid cancer	4.68e-05	0.000104	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PTEN—thyroid cancer	4.52e-05	0.0001	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—AKT1—thyroid cancer	4.44e-05	9.85e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—RXRA—thyroid cancer	4.07e-05	9.03e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—NRAS—thyroid cancer	4.03e-05	8.95e-05	CbGpPWpGaD
Danazol—ESR1—Gene Expression—AKT1—thyroid cancer	4.01e-05	8.89e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—AKT1—thyroid cancer	3.48e-05	7.73e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—KRAS—thyroid cancer	3.47e-05	7.71e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TP53—thyroid cancer	3.09e-05	6.85e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—HRAS—thyroid cancer	2.95e-05	6.55e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—AKT1—thyroid cancer	2.61e-05	5.78e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PPARG—thyroid cancer	2.57e-05	5.7e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.02e-05	4.49e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PTEN—thyroid cancer	1.76e-05	3.91e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—AKT1—thyroid cancer	1.02e-05	2.25e-05	CbGpPWpGaD
